Vista Pharma Q1 FY26: Rs 98.6 lakh loss, zero sales

What Vista Pharmaceuticals reported this quarter

Vista Pharmaceuticals Limited reported a net loss of Rs 98.59 lakh for the quarter ended June 30, 2026 (Q1 FY26). The loss narrowed compared with a net loss of Rs 129.04 lakh in the corresponding quarter last year (Q1 FY25). The key headline was the absence of operating revenue in the quarter, with revenue from operations reported at nil. In Q1 FY25, the company had reported revenue from operations of Rs 151.88 lakh. The quarter’s total income stood at Rs 3.99 lakh, and it was entirely classified as other income.

Q1 FY26 revenue: operations at nil

The company recorded zero revenue from operations in Q1 FY26, a 100% decline from Rs 151.88 lakh a year ago. With no operational revenue, total income of Rs 3.99 lakh came only from other income. In Q1 FY25, other income was shown as Rs 0 lakh in the data provided. The result is that the quarter’s performance was largely defined by cost control and non-operating items rather than business volumes. The company also reported zero revenue from operations for the quarter ended March 31, 2026, indicating consecutive quarters with no operating revenue.

Expenses dropped sharply year-on-year

Total expenses for Q1 FY26 were Rs 136.70 lakh, down from Rs 299.88 lakh in Q1 FY25. The expense base was led by employee benefits of Rs 51.15 lakh and finance costs of Rs 33.59 lakh. The reduction in expenses was a major contributor to the narrower loss versus the previous year. However, with operational revenue at zero, the cost structure still resulted in a sizable loss for the quarter. The expense mix also highlights that fixed and financing costs remained meaningful despite nil operating sales.

Profit before tax narrowed, helped by tax credit

Profit before tax (PBT) for Q1 FY26 was a loss of Rs 132.71 lakh, improving from a loss of Rs 148.01 lakh in Q1 FY25. The company reported deferred tax credits of Rs 34.12 lakh, which reduced the final net loss position. After accounting for these tax effects, the net loss was reported at Rs 98.59 lakh. In simple terms, the quarterly loss narrowed on lower expenses and the impact of deferred tax credits, even though operating revenue was absent.

Working capital position: negative as of June 30, 2026

As of June 30, 2026, the company reported that current liabilities exceeded current assets by Rs 183.32 lakh. This indicates negative working capital at the end of the quarter. Negative working capital can reflect near-term liquidity strain, since obligations due within a year are higher than assets expected to convert to cash within the same period. The disclosure adds balance sheet context to the income statement, especially in a period when revenue from operations was nil.

How Q1 compares with recent quarters and FY26

The company also disclosed that for the quarter ended March 31, 2026, it reported a net loss of Rs 586.29 lakh with zero revenue from operations. For the financial year ended March 31, 2026 (FY26), Vista Pharmaceuticals reported a net loss of Rs 1,206.12 lakh, compared with a net loss of Rs 464.87 lakh in FY25. Revenue from operations for FY26 was Rs 539.95 lakh, down from Rs 1,007.46 lakh in FY25. These annual figures show that FY26 was a weaker year than FY25 on both sales and profitability metrics.

Key reported metrics at a glance (all figures in Rs lakh)

Stock and market datapoints referenced

The dataset referenced a move of -0.34 ( -4.93% ) as on 14 Aug, 2026 at 09:29. It also stated a current share price of Rs 6.63 for Vista Pharmaceutical. The same set of information mentioned “No Earnings Data” for EPS in the context provided. Investors typically read these datapoints alongside quarterly numbers to understand how the market is reacting and what financial metrics are available for tracking performance.

Board meeting and compliance update

A board meeting intimation was also referenced for approval of unaudited financial results for the quarter ended 30.06.2026, scheduled on 14/08/2026. Such intimations are part of routine disclosure and governance processes for listed companies. The company is listed on BSE with the scrip code 524711, and the ISIN shown was INE427C01021. The sector classification provided was Pharmaceuticals.

Company profile in brief

Vista Pharmaceuticals Limited manufactures and sells pharmaceutical, medical, and veterinary preparations, including a range of generic drug products. The Q1 FY26 results show a quarter where operating revenue did not contribute to income, and the reported numbers were shaped by other income, expense levels, finance costs, and tax adjustments. The balance sheet note on negative working capital adds an additional operational and liquidity lens for readers tracking the company.

Conclusion

Vista Pharmaceuticals’ Q1 FY26 print showed a narrower net loss of Rs 98.59 lakh despite nil revenue from operations, primarily due to sharply lower expenses and deferred tax credits of Rs 34.12 lakh. The company’s disclosures also highlighted negative working capital of Rs 183.32 lakh as of June 30, 2026. The next formal checkpoint for investors is the company’s regulatory cycle around board and exchange disclosures tied to the unaudited quarterly financials for the period ended 30.06.2026.